Simplex Trading’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $235K | Buy |
+24,086
| New | +$209K | ﹤0.01% | 4503 |
|
|
2026
Q1 | – | Sell |
-32,868
| Closed | -$251K | – | 9637 |
|
|
2025
Q4 | $242K | Buy |
32,868
+27,006
| +461% | +$165K | ﹤0.01% | 4032 |
|
|
2025
Q3 | $38K | Sell |
5,862
-2,371
| -29% | -$12.8K | ﹤0.01% | 6725 |
|
|
2025
Q2 | $35K | Buy |
+8,233
| New | +$40.4K | ﹤0.01% | 6265 |
|
|
2024
Q2 | – | Sell |
-3,732
| Closed | -$61.8K | – | 9334 |
|
|
2024
Q1 | $84K | Buy |
3,732
+2,332
| +167% | +$40.9K | ﹤0.01% | 5761 |
|
|
2023
Q4 | $18K | Sell |
1,400
-34
| -2% | -$458 | ﹤0.01% | 7004 |
|
|
2023
Q3 | $28K | Buy |
+1,434
| New | +$32.2K | ﹤0.01% | 6318 |
|
|
2023
Q1 | – | Sell |
-1,160
| Closed | -$57.3K | – | 9599 |
|
|
2022
Q4 | $59K | Buy |
1,160
+772
| +199% | +$53.5K | ﹤0.01% | 5663 |
|
|
2022
Q3 | $31K | Sell |
388
-70
| -15% | -$5.23K | ﹤0.01% | 7027 |
|
|
2022
Q2 | $30K | Buy |
+458
| New | +$42K | ﹤0.01% | 7152 |
|
|
2022
Q1 | – | Sell |
-3,916
| Closed | -$488K | – | 10931 |
|
|
2021
Q4 | $377K | Buy |
+3,916
| New | +$390K | ﹤0.01% | 4217 |
|
|
2021
Q3 | – | Sell |
-19
| Closed | -$1.97K | – | 9821 |
|
|
2021
Q2 | $2K | Sell |
19
-188
| -91% | -$27.3K | ﹤0.01% | 9718 |
|
|
2021
Q1 | $0 | Sell |
207
-553
| -73% | -$117K | ﹤0.01% | 9431 |
|
|
2020
Q4 | $176K | Buy |
760
+67
| +10% | +$15.5K | ﹤0.01% | 4784 |
|
|
2020
Q3 | $151K | Sell |
693
-620
| -47% | -$152K | ﹤0.01% | 4456 |
|
|
2020
Q2 | $372K | Buy |
+1,313
| New | +$388K | ﹤0.01% | 3265 |
|
|
2020
Q1 | – | Sell |
-1,735
| Closed | -$479K | – | 7930 |
|
|
2019
Q4 | $498K | Buy |
1,735
+1,644
| +1,807% | +$357K | ﹤0.01% | 2763 |
|
|
2019
Q3 | $13K | Sell |
91
-3,116
| -97% | -$422K | ﹤0.01% | 6093 |
|
|
2019
Q2 | $288K | Buy |
3,207
+2,408
| +301% | +$193K | ﹤0.01% | 3112 |
|
|
2019
Q1 | $69K | Sell |
799
-406
| -34% | -$45K | ﹤0.01% | 4716 |
|
|
2018
Q4 | $169K | Buy |
1,205
+1,113
| +1,210% | +$188K | ﹤0.01% | 3329 |
|
|
2018
Q3 | $23K | Buy |
+92
| New | +$25.4K | ﹤0.01% | 5838 |
|
|
2018
Q2 | – | Sell |
-1,454
| Closed | -$360K | – | 7633 |
|
|
2018
Q1 | $292K | Buy |
1,454
+1,011
| +228% | +$202K | 0.01% | 1000 |
|
|
2017
Q4 | $63K | Sell |
443
-824
| -65% | -$132K | ﹤0.01% | 2218 |
|
|
2017
Q3 | $208K | Buy |
+1,267
| New | +$181K | 0.01% | 1162 |
|
|
2017
Q2 | – | Sell |
-2,516
| Closed | -$372K | – | 6461 |
|
|
2017
Q1 | $484K | Buy |
+2,516
| New | +$404K | 0.02% | 692 |
|
|
2016
Q2 | – | Sell |
-135
| Closed | -$17.5K | – | 6145 |
|
|
2016
Q1 | $18K | Sell |
135
-51
| -27% | -$5.63K | ﹤0.01% | 2903 |
|
|
2015
Q4 | $36K | Sell |
186
-618
| -77% | -$134K | ﹤0.01% | 2185 |
|
|
2015
Q3 | $126K | Buy |
804
+767
| +2,073% | +$205K | 0.01% | 1232 |
|
|
2015
Q2 | $15K | Buy |
+37
| New | +$16K | ﹤0.01% | 2717 |
|
|
2015
Q1 | – | Sell |
-36
| Closed | -$15.5K | – | 5262 |
|
|
2014
Q4 | $20K | Buy |
+36
| New | +$20.4K | ﹤0.01% | 2057 |
|
Other funds holding KPTI
RCM
ACA
CCM
APM
Simplex Trading's KPTI Position: Q2 2026 in Review
Simplex Trading opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 24,086 shares worth $235K. The stake represents ﹤0.01% of the portfolio and ranks #4503 among its holdings. This is a return to the name: Simplex Trading previously reported a position in KPTI as recently as Q4 2025.
Simplex Trading first reported a position in KPTI in Q4 2014 and has held it in 31 quarters since. The position peaked at $498K in Q4 2019. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.
- Simplex Trading held 24,086 shares of Karyopharm Therapeutics worth $235K as of Q2 2026.
- Karyopharm Therapeutics was a new Simplex Trading position in Q2 2026.
- Karyopharm Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4503 holding.
- Simplex Trading first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 31 quarters since.
- Simplex Trading's Karyopharm Therapeutics position peaked at $498K in Q4 2019.
- 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.